Frost M, et al. - Subcutaneous buprenorphine (CAM2038) weekly and monthly depots were investigated for long-term safety in this phase 3, open-label, observational, multicentre 48-week trial conducted at 26 outpatient sites (US, UK, Hungary, Denmark, Sweden, Germany, Australia). Researchers administered CAM2038 weekly (8, 16, 24, or 32 mg) or monthly (64, 96, 128, or 160 mg) with flexible dosing and individualized titration utilizing multiple CAM2038 weekly and monthly doses to 227 adults with opioid use disorder (37 initiated onto CAM2038 and 190 converted from sublingual buprenorphine). Patients well tolerated subcutaneous buprenorphine delivered weekly or monthly (CAM2038) with a systemic safety profile consistent with the known profile of sublingual buprenorphine. They noted high retention rates and low levels of illicit opioid use in correlation to CAM2038 weekly and monthly, throughout this study.